Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Aligos Therapeutics (ALGS) Leases (2021 - 2025)

Aligos Therapeutics' Leases history spans 5 years, with the latest figure at $3.1 million for Q4 2025.

  • For Q4 2025, Leases fell 37.77% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $3.1 million, down 37.77%, while the annual FY2025 figure was $3.1 million, 37.77% down from the prior year.
  • Leases reached $3.1 million in Q4 2025 per ALGS's latest filing, down from $3.6 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $8.8 million in Q4 2021 to a low of $3.1 million in Q4 2025.
  • Average Leases over 5 years is $6.4 million, with a median of $6.8 million recorded in 2021.
  • Peak YoY movement for Leases: increased 25.99% in 2022, then tumbled 37.77% in 2025.
  • A 5-year view of Leases shows it stood at $8.8 million in 2021, then fell by 12.41% to $7.7 million in 2022, then decreased by 14.8% to $6.6 million in 2023, then decreased by 24.32% to $5.0 million in 2024, then tumbled by 37.77% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Leases are $3.1 million (Q4 2025), $3.6 million (Q3 2025), and $4.1 million (Q2 2025).